Enhanced formation and survival of CD4⁺ CD25^hi Foxp3⁺ T-cells in chronic lymphocytic leukemia

References

• Porakishvili N, Roschupkina T, Kalber T, Jewell A P, Patterson K, Yong K, et al. Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL). Clin Exp Immunol 2001; 126: 29–36
   PubMed Web of Science ®Google Scholar
• Serrano D, Monteiro J, Allen S L, Kolitz J, Schulman P, Lichtman S M, et al. Clonal expansion within the CD4+ CD57+ and CD8+ CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol 1997; 158: 1482–1489
   PubMed Web of Science ®Google Scholar
• Mackus W J, Frakking F N, Grummels A, Gamadia L E, De Bree G J, Hamann D, et al. Expansion of CMV-specific CD8+ CD45RA+ CD27− T cells in B-cell chronic lymphocytic leukemia. Blood 2003; 102: 1057–1063
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, et al. Reduced frequencies and suppressive function of CD4+ CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018–2025
   PubMed Web of Science ®Google Scholar
• Clarke S L, Betts G J, Plant A, Wright K L, El-Shanawany T M, Harrop R, et al. CD4+ CD25+ FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 2006; 1: e129
   PubMed Web of Science ®Google Scholar
• Curiel T J, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942–949
   PubMed Web of Science ®Google Scholar
• Seddiki N, Santner-Nanan B, Tangye S G, Alexander S I, Solomon M, Lee S, et al. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood 2006; 107: 2830–2838
   PubMed Web of Science ®Google Scholar
• Akbar A N, Vukmanovic-Stejic M, Taams L S, Macallan D C. The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery. Nat Rev Immunol 2007; 7: 231–237
   PubMed Web of Science ®Google Scholar
• Vukmanovic-Stejic M, Zhang Y, Cook J E, Fletcher J M, McQuaid A, Masters J E, et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 2006; 116: 2423–2433
   PubMed Web of Science ®Google Scholar
• Fritzsching B, Oberle N, Eberhardt N, Quick S, Haas J, Wildemann B, et al. In contrast to effector T cells, CD4+ CD25+ FoxP3+ regulatory T cells are highly susceptible to CD95 ligand – but not to TCR-mediated cell death. J Immunol 2005; 175: 32–36
   PubMed Web of Science ®Google Scholar
• Taams L S, Smith J, Rustin M H, Salmon M, Poulter L W, Akbar A N. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 2001; 31: 1122–1131
   PubMed Web of Science ®Google Scholar
• Maslanka K, Piatek T, Gorski J, Yassai M, Gorski J. Molecular analysis of T cell repertoires. Spectratypes generated by multiplex polymerase chain reaction and evaluated by radioactivity or fluorescence. Hum Immunol 1995; 44: 28–34
   PubMed Web of Science ®Google Scholar
• Kater A P, Evers L M, Remmerswaal E B, Jaspers A, Oosterwijk M F, van Lier R A, et al. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 2004; 127: 404–415
   PubMed Web of Science ®Google Scholar
• Uss E, Rowshani A T, Hooibrink B, Lardy N M, van Lier R A, ten Berge I J. CD103 is a marker for alloantigen-induced regulatory CD8+ T cells. J Immunol 2006; 177: 2775–2783
   PubMed Web of Science ®Google Scholar
• Hintzen R Q, Lens S M, Beckmann M P, Goodwin R G, Lynch D, van Lier R A. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J Immunol 1994; 152: 1762–1773
   PubMed Web of Science ®Google Scholar
• Eldering E, Spek C A, Aberson H L, Grummels A, Derks I A, de Vos A F, et al. Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. Nucleic Acids Res 2003; 31: e153
   PubMed Web of Science ®Google Scholar
• Mackus W J, Kater A P, Grummels A, Evers L M, Hooijbrink B, Kramer M H, et al. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. Leukemia 2005; 19: 427–434
   PubMed Web of Science ®Google Scholar
• van Leeuwen E M, Remmerswaal E B, Heemskerk M H, ten Berg I J, van Lier R A. Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood 2006; 108: 3121–3127
   PubMed Web of Science ®Google Scholar
• Liu W, Putnam A L, Xu-Yu Z, Szot G L, Lee M R, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701–1711
   PubMed Web of Science ®Google Scholar
• Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)- 2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203: 1693–1700
   PubMed Web of Science ®Google Scholar
• Yang Z Z, Novak A J, Ziesmer S C, Witzig T E, Ansell S M. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+ CD25 T cells. Blood 2007; 110: 2537–2544
   PubMed Web of Science ®Google Scholar
• Smit L A, Hallaert D Y, Spijker R, de G B, Jaspers A, Kater A P, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007; 109: 1660–1668
   PubMed Web of Science ®Google Scholar
• Ranheim E A, Cantwell M J, Kipps T J. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995; 85: 3556–3565
   PubMed Web of Science ®Google Scholar
• Hallaert D Y, Spijker R, Jak M, Derks I A, Alves N L, Wensveen F M, et al. Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. Cell Death Differ 2007; 14: 1958–1967
   PubMed Web of Science ®Google Scholar
• Vince J E, Wong W W, Khan N, Feltham R, Chau D, Ahmed A U, et al. IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 2007; 131: 682–693
   PubMed Web of Science ®Google Scholar
• Wang L, Du F, Wang X. TNF-α induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693–703
   PubMed Web of Science ®Google Scholar
• Miyawaki T, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S, et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 1992; 149: 3753–3758
   PubMed Web of Science ®Google Scholar
• Mittal S, Marshall N A, Duncan L, Culligan D J, Barker R N, Vickers M A. Local and systemic induction of CD4+ CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008; 111: 5359–5370
   PubMed Web of Science ®Google Scholar
• Schmid C, Isaacson P G. Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 1994; 24: 445–451
   PubMed Web of Science ®Google Scholar
• Kitada S, Zapata J M, Andreeff M, Reed J C. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 106: 995–1004
   PubMed Web of Science ®Google Scholar
• Ghia P, Strola G, Granziero L, Geuna M, Guida G, Sallusto F, et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+ , CD40L+ T cells by producing CCL22. Eur J Immunol 2002; 32: 1403–1413
   PubMed Web of Science ®Google Scholar
• Arens R, Baars P A, Jak M, Tesselaar K, van der Valk M, Van Oers M H, et al. Cutting edge: CD95 maintains effector T cell homeostasis in chronic immune activation. J Immunol 2005; 174: 5915–5920
   PubMed Web of Science ®Google Scholar
• Walker M R, Kasprowicz D J, Gersuk V H, Benard A, Van L M, Buckner J H, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+. J Clin Invest 2003; 112: 1437–1443
   PubMed Web of Science ®Google Scholar
• Wang J, Ioan-Facsinay A, van der Voort E I, Huizinga T W, Toes R E. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007; 37: 129–138
   PubMed Web of Science ®Google Scholar
• McKenzie M D, Carrington E M, Kaufmann T, Strasser A, Huang D C, Kay T W, et al. Proapoptotic BH3-only protein Bid is essential for death receptor-induced apoptosis of pancreatic beta-cells. Diabetes 2008; 57: 1284–1292
   PubMed Web of Science ®Google Scholar
• Cesana G C, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, et al. Characterization of CD4+ CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24: 1169–1177
   PubMed Web of Science ®Google Scholar
• Liyanage U K, Moore T T, Joo H G, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756–2761
   PubMed Web of Science ®Google Scholar
• Wolf A M, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9: 606–612
   PubMed Web of Science ®Google Scholar
• Miller A M, Lundberg K, Ozenci V, Banham A H, Hellstrom M, Egevad L, et al. CD4+ CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006; 177: 7398–7405
   PubMed Web of Science ®Google Scholar
• Quezada S A, Peggs K S, Curran M A, Allison J P. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006; 116: 1935–1945
   PubMed Web of Science ®Google Scholar
• Hodi F S, Butler M, Oble D A, Seiden M V, Haluska F G, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105: 3005–3010
   PubMed Web of Science ®Google Scholar
• Hahntow I N, Schneller F, Oelsner M, Weick K, Ringshausen I, Fend F, et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004; 18: 747–755
   PubMed Web of Science ®Google Scholar
• Schlagbauer-Wadl H, Klosner G, Heere-Ress E, Waltering S, Moll I, Wolff K, et al. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J Invest Dermatol 2000; 114: 725–730
   PubMed Web of Science ®Google Scholar
• O'Brien S, Moore J O, Boyd T E, Larratt L M, Skotnicki A, Koziner B, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 1114–1120
   PubMed Web of Science ®Google Scholar